Non PUVA nonsurgical therapies for vitiligo

Clinics in Dermatology

Volumn 15, Issue 6, 1997, Pages 907-919

  Mandel, Arkady S ^a   Haberman, Herbert F ^a   Pawlowski, Frcpc Danuta ^a   Goldstein, Eric ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BETAMETHASONE VALERATE; CANTHAXANTHIN; CATALASE; CHLORMETHINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYSTINE; DESONIDE; DEXAMETHASONE; DIMETHYL SULFOXIDE; FLUOCINONIDE; FOLIC ACID; HALOMETASONE; HYDROCORTISONE; INTERMEDIN DERIVATIVE; KHELLIN; LEVAMISOLE; LEVODOPA; MELAGENINA; METHISOPRINOL; MONOBENZONE; PHENYLALANINE; PLACENTA EXTRACT; PREDNISONE; PSORALEN; TRIAMCINOLONE ACETONIDE; TYROSINE; UNCLASSIFIED DRUG;

ACNE; BLEACHING; CHINESE MEDICINE; CLINICAL TRIAL; ECCHYMOSIS; ERYTHEMA; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; LASER SURGERY; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PHOTOTHERAPY; PRIORITY JOURNAL; PSYCHOTHERAPY; PUVA; REVIEW; ROSACEA; SKIN ALLERGY; SKIN ATROPHY; TOPICAL DRUG ADMINISTRATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITILIGO; XERODERMA PIGMENTOSUM;

EID: 0030727764     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00132-6     Document Type: Article

References (80)

1. Goldstein E, Haberman HF, Manon IA, et IJ. Non-psoralen treatment of vitiligo. Part 1. Int i Dermatol 1993;31: 229-36.
2. Goldstein E, Haberman HF, Manon l A, et al. Non-psoralen treatment of vitiligo. Part II. Int I Dermatol 1993;31: 314-9.
3. Kandil E. Vitiligo-response to 0.2% betamethasone 17-valerate in flexible collodion. Dermatologica 1970; 141:277-81.
4. Koopmans-van Dorp B, Goedhart-van Dijk B, Neering HE, et al. Treatment of vitiligo by local application of betamethasone 17-valerate in a dimethyl sulfoxide cream base. Dermatologica 1973;146:310-4.
5. Kandil E. Treatment of vitiligo with 0.1% betamethasone 17-valerate in isopropyl alcohol-a double-blind trial. Br J Dermatol 1974;91:457-60.
6. Bleehen SS. The treatment of vitiligo with topical corticosteroids. Light and electromicroscopic studies. Br 1 Dermatol 1976;94(suppl 12):43-50.
7. Clayton R. A double blind trial of 0.05% clobetasol propionate in the treatment of vitiligo. Br J Dermatol 1977;96: 71-3.
8. Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984;120:631-5.
9. Guozhu H, Changgeng S, Ganyun Y, et al. The therapeutic effect of sicorten ointment in patients with vitiligo. Br J Clin Pract 1985;434-5.
10. Koga M. Vitiligo: A new classification and therapy. Br J Dermatol 1977;97:255-61.
11. Geraldez CB, Gutierrez GT. A clinical trial of clobetasol propionate in Filipino vitiligo patients. Clin Ther 1987;9: 474-82.
12. Gokhaie BB, Gokhaie TB. Corticotrophin and vitiligo (preliminary observations). Br ] Dermatol 1976;95:329.
13. Hernandez-Perez E. Vitiligo treated with ACTH. Int J Dermatol 1979;18:578-9.
14. Imamura S, Tagami H. Treatment of vitiligo with oral corticosteroids. Dermatologica 1976;153:179-85.
15. Brostoff H, Brostoff J. Vitiligo and steroids. Lancet 1978;2:688.
16. Thomas PS. Prednisolone causing amelioration of both vitiligo and chronic active hepatitis. Br J Hosp Med 1987;38:464.
17. Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreding disease. Int J Dermatol 1993;32:753-7.
18. Kanwar AJ, Dhar S, Dawn G. Oral minipulse therapy in vitiligo. Dermatologica 1995;190:251-2.
19. Muto M, Furumoto H, Ohmura A, et al. Successful treatment of vitiligo with a sex steroid-thyroid hormone mixture. J Dermatol 1995;22:770-2.
20. Kandil E. Treatment of localized vitiligo with intradermal injections of triamcinolone acetonide. Dermatologica 1970;140:195-206.
21. Vasistha LK, Singh G. Vitiligo and intralesional steroids. Indian J Med Res 1979;69:308-11.
22. Cormane RH, Siddiqui AH, Westerhoff W, et al. Phenylalanine and UVA light for the treatment of vitiligo. Arch Dermatol Res 1985;277:126-30.
23. Westchrof W, Groot I, Krieg SR, et al. Langerhans cell population studies with OKT6 and HLA-DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA irradiation. Acta Derm Venerol 1986; 66:259-62.
24. Kuiters GR, Hup JM, Siddiqui AH, et al. Oral phenylalanine loading and sunlight as source of UVA irradiation in vitiligo on the Caribbean island of Curacao. J Trop Med Hyg 1986;89:149-55.
25. Antonio C, Schulpis H, Michas T, et al. Vitiligo therapy with oral and topical phenylalanine with UVA exposures. Int J Dermatol 1989;28:545-7.
26. Schulpis CH, Antoniou C, Michas T, et al. Phenylalanine plus ultraviolet light: preliminary report of a promising treatment for childhood vitiligo. Pediatr Dermatol 1989;6:332-5.
27. Siddiqui AH, Stolk LML, Bhaggoe R, et al. L-Phenylalanine and UVA Irradiation in the treatment of vitiligo. J Dermatol 1994;188:215-8.
28. Beretti B, Grupper CH, Bermejo D, et al. PUVA 5-MOP and PUVA 5-MOP + phenylalanine in the treatment of vitiligo. In: Fitzpatrick TB, Forlot P, Pathak MA, et al, editors. Psoralens: past, present and future of photoche-moprotection and other biological activities. Paris: Libbey, Eurotex, 1989:103-8.
29. Biella U, Haustein UF. Die Behandlung der Vitiligo mit UV and Phenylalanin. Dtsch Dermatol 1990;38:1063-4.
30. Abdel-Fattah A, Aboul-Enein MN, Wassel G, et al An approach to the treatment of vitiligo by khellin. Dermatologica 1982;165:136-40.
31. Morliere P, Honigsmann H, Averbeck D, et al. Phototherapeutic, photobiologic, and photosensitizing properties of khellin. J Invest Dermatol 1988;90:720-4.
32. Ortel B, Tanew A, Honigsmann H. Vitiligo treatment. Curr Probl Dermatol 1986;15:265-71.
33. Tritrungtasna O, Jerasutus S, Suvanprakon P. Treatment of alopecia areata with khellin and UVA. Int J Dermatol 1993;32:690.
34. Ortel B, Tanew A, Honigsmann H. Treatment of vitiligo with khellin and ultraviolet. J Am Acad Dermatol 1988;18:693-701.
35. Dushet P, Schwarz T, Pusch M, et al. Marked increase of liver transaminases after khellin and UVA therapy. J Am Acad Dermatol 1989;21:592-3.
36. Honigsmann H, Ortel B, Tanew A. Reply to the editor. J Am Acad Dermatol 1989;21:593-4.
37. Orecchia G, Perfetti L. Photochemotherapy with topical khellin and sunlight in vitiligo. J Dermatol 1992; 184:120-3.
38. Jaworsky C, Ratz JL, Dijkstra JWE. Efficacy of tan accelerators. J Am Acad Dermatol 1987;16:769-71.
39. Woolfson H, Finn OA. Topical levodopa in vitiligo. Lancet 1972;1:598.
40. Goolamali SK. Levodopa in vitiligo. Lancet 1973;i:675-6.
41. Miyares Cao C, Taboas M, Lopez M. Informe prelimenar sobre el empleo de extracto placentario humano en la terapeutica vitiligo. Rev Cub Farm 1976;10:67-72.
42. Miyares Cao C, Taboas M. Placental alpha-lipoprotein for stimulating the synthesis of melanin. Patent. Ger-OffenDe-3229-738 (Ch-AGl-K-37-07) February, 16, 1984.
43. Miyares Cao C. Melagenine: A Cuban product. A new and effective drug for the treatment of vitiligo. Series of National Reports. Republic of Cuba, Havana, 1986:3-101.
44. Miyares Cao C. Melagenina: 16 anos de experiencia Cubana en al tratamiento del vitiligo. In: La melagenina, nuevo medicamento Cubano para el tratamento del vitiligo. La Habana, Cuba: Impreso, 1989:3-20.
45. Ayala O. Experiencias con el empleo de la melagenina en Colombia. In: La melagenina, nuevo medicamento Cubano para el tratamento del vitiligo. La Habana, Cuba: Impreso, 1989:69-71.
46. Hollands I. Demostraction ultraestructural de la accion melanogenica de las melageninas I y II. In: La melagenina, nuevo medicamento Cubano para el tratamento del vitiligo. La Habana, Cuba: Impreso, 1989:29-33.
47. Suite M, Quamina DB. Treatment of vitiligo with topical melagenine-a human placental extract. J Am Acad Dermatol 1991;24:1018-9.
48. Nordlund JJ, Halder R. Melagenina. An analysis of published and other available data. Dermatologica 1990;181:1-4.
49. Nordlund JJ, Halder RM. Management of vitiligo. Dermatol Clin 1993;11:27-33.
50. Azambuja RD. Melagenina and vitiligo. Dermatology 1992;184:153-4.
51. Nordlund Jj. Reply. Dermatology 1992;184:154-5.
52. Shao C, Ye G. Current treatment of vitiligo in China. Chin Med J 1995;108:647-9.
53. Tsuji T, Hamada T. Topically administered fluorouracil in vitiligo. Arch Dermatol 1983;! 19:722-7.
54. Monk B. Topical fluorouracil in vitiligo. Arch Dermatol 1985;121:25-6.
55. Szekeres E, Morvay M. Repigmentation of vitiligo macules treated topically with efudex cream. Dermatologica 1985;171:55-9.
56. Lerner AB, Snell RS, Chanco-Turner ML, et al. Vitiligo and sympathectomy. Arch Dermatol 1966;94:269-78.
57. Hadley ME, Abdel-Malek ZA, Marwan MM, et al. [Nle4,D-Phe7]a-MSH: A superpotent melanotropin that "irreversibly" activates melanoma tyrosinase. Endocr Res Commun 1985;11:157-70.
58. Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA 1991;266:2730-6.
59. Nordlund JJ. a-Melanocyte stimulating hormone: A ubiquitous cytokine with pigmenting effects. JAMA 1991;266:2753-4
60. Mandel ASH. The influence of laser therapy on the content of serotonin and dopamine in patients with focal scleroderma. Vestn Dermatol Venerol 1982;8:13-17.
61. Mandel ASH. Skin repigmentation after laser therapy. Vestn Dermatol Venerol 1984;September:26-9.
62. Schallreuter KU, Wood JM, Pittelkow MR, et al. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science 1994;263:1444-6.
63. Schallreuter KU, Wood JM, Ziegler I, et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta 1994; 1226:181-92.
64. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991;97:1081-85.
65. Schallreuter KU, Wood JM, Lemke KR, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-tern) UVB exposure: A case study on 33 patients. Dermatology 1995;190:223-9.
66. Pasricha JS, Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreding disease. Int J Dermatol 1994;33:584-7.
67. Gokhale BB. Cyclophosphamide and vitiligo. IntJ Dermatol 1979;18:92.
68. Gupta AK, Ellis CM, Nickoloff BI, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. Arch Dermatol 1990;! 26:3 W -50.
69. Csaszar T, Patakfalvi A. Treatment of polyglandular autoimmune syndrome with cydosporin-A. Acta Medica Hungarica 1992-93;49:187-93.
70. Van Scott EJ, Yu RJ. Melanogenesis from topical mechlorethamine and analogues in skin of hairless mice and in vitiligo. J Invest Dermatol 1975:65:476 8.
71. Grimes PE. Vitiligo. An overview uf therapeutic approaches. Dermatol Clin 1993; 11:32.
72. White GL, Beesley R, Thiese SM, et ai. Retina! crystals and oral tanning agents. Am Fam Physician 1988:37:125-6.
73. Orecchia G, Perfetti L. Cystine in the treatment of vitiligo. G Ital Dermatol Venereol 1989;12452-31.
74. Koshevenko IUN. Alpha-tocopherol in the combined treatment of vitiligo. Vesht Dermatol Venerol 1989:70-2.
75. Oliver EA, Schwartz L, Warren L.H. Occupational leucoderma. Arch Dermatol Syphylol 1940:12:993-1014.
76. Engasser PG, Maibach HI. Cosmetic, and dermatology: Bleaching creams. ] Am Acad Dermatol 1981.5:143-7.
77. Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzyl ether of hydroquinone. Br J Dermatol 1977;97:669-79.
78. Canizares O, Jaramillo FU, Vegas FK. I eukomelanoderma subsequent to the application of monobemvl ether of hydroquinone. Arch Dermatol 1958;77:220-1.
79. Catona A, Lanzer D. Monobenzone, superfade, vitiligo and confetti-like depigmentation. Mi d i Aust 1987;146:320-1.
80. Verallo-Rowell VM, Verallo V, Graupe K, et al., Doubleblind comparision of azelaic add and hydroquinone in the treatment of melasma: A new therapeutic agent. 17th World Congress of Dermatology, Berlin, May, 1989. Acta Dermatol Venereol Suppl (Stockh) 19H9;143:58-6l.